Sudden death after valve-in-valve procedure due to delayed coronary obstruction: A case report by Buscaglia, Angelo et al.
CASE REPORT Open Access
Sudden death after valve-in-valve
procedure due to delayed coronary
obstruction: a case report
Angelo Buscaglia*†, Giacomo Tini†, Gian Paolo Bezante, Claudio Brunelli and Manrico Balbi
Abstract
Background: Valve-in-valve transcatheter aortic valve implantation for degenerated aortic bioprostheses is an effective
option for patients at high risk for redo surgery, even if it may be burdened by complications more common in specific
settings, such as, coronary artery obstruction.
Case presentation: We present the case of a Caucasic 84-year-old woman with degeneration of a previously
implanted aortic Mitroflow bioprosthesis. She underwent a valve-in-valve transcatheter aortic valve implantation
with a CoreValve® bioprosthesis. End-procedure coronary angiography demonstrated maintained perfusion of
both coronary arteries. However, few hours later, she experienced sudden cardiac death. An autopsy showed that
Mitroflow prosthesis leaflets were higher than the left main coronary ostium, and no other possible cause for the
sudden death. Fatality was thus ascribed to left main coronary ostium obstruction due to apposition of the
Mitroflow leaflet pushed upward by the late expansion of CoreValve®.
Conclusions: Coronary artery obstruction is a frequently fatal complication which usually presents just after valve
implantation, but, as reported in our case, it may also have a delayed presentation. Accurate patient’s selection
and intraoperative preventive measures can reduce this eventuality.
Keywords: Transcatheter aortic valve implantation, Valve-in-valve, Coronary artery obstruction, Degenerated aortic
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Background
In recent years, valve-in-valve (VIV) transcatheter aortic
valve implantation (TAVI) procedures for correction of
degenerated aortic bioprostheses appeared to be a feasible
and satisfactory option for patients deemed at high risk
for redo surgery [1]. However, the efficacy of this method
has been reported to be lower in specific settings. In par-
ticular, there are concerns about higher residual transvalv-
ular gradients and rate of coronary artery obstruction [2].
We present a case of sudden death which occurred
few hours after a successful VIV intervention. The only
possible explanation for the event, as demonstrated by
autopsy, appeared to be left main coronary ostium
(LMCO) obstruction caused by the previously surgically
implanted aortic valve’s leaflets, pushed upward by the
expansion of the CoreValve® used for the VIV procedure.
Case presentation
We report the case of a retired Caucasic 84-year-old
woman who required a VIV procedure due to the degen-
eration of a previously implanted aortic bioprosthesis.
Her cardiologic history started in 2006 when she experi-
enced syncope and was then diagnosed as having severe
aortic stenosis (mean transvalvular gradient 44 mmHg)
and severe mitral regurgitation. She reported no previ-
ous clinical events. She underwent aortic valve replace-
ment with a Mitroflow number 21 bioprosthesis and a
Carpentier-Edwards Physio mitral annuloplasty ring im-
plantation. After surgery, she suffered from brady-tachy
syndrome and needed a pacemaker implantation.
The initial signs of prosthesis degeneration were found
at a routine transthoracic echocardiography (TTE) in
2011, with a transvalvular mean gradient of 26 mmHg.
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However, she was asymptomatic and meanwhile she was
diagnosed as having an indolent myeloma, thus a con-
servative approach was chosen.
In January 2014, she started complaining of epigas-
tric discomfort and dyspnea for minimal exertion. A
TTE was repeated and showed a further increase of
the mean transvalvular gradient (35 mmHg) and
occurrence of moderate paraprosthetic regurgitation
due to detachment of the anterior edge of the aortic
prosthesis ring.
In February 2014 she was admitted to our department
for an episode of pulmonary edema with angina. A
physical examination revealed bilateral crackles, 3/6
systolic ejection murmur, and leg swelling. Neurological
evaluation was normal. Her electrocardiogram showed
transient diffuse ST segment depression and troponin
values were slightly elevated (peak, 0.08 ng/ml; refer-
ence values, < 0.015 ng/ml). In addition, laboratory tests
showed a mild anemia (hemoglobin values, 11 g/dl; ref-
erence values, 13–17 g/dl) and a stage 3 chronic kidney
disease (serum creatinine, 1.1 mg/dl; reference values,
0.5–1 mg/dl; and glomerular filtration rate, 47 mg/dl).
Her hepatic function was normal, as well as white
blood cells and platelets count (white blood cells, 6500/
ml; reference values, 4500–9800; and platelets count,
300 000/ml; reference values, 150,000–450,000).
A transesophageal echocardiogram (TEE) showed hypo-
mobility of the non-coronary cusp, moderate paraprosthetic
regurgitation, and severe intraprosthetic regurgitation. Due
to the frailty of our patient, in consideration of age, previ-
ous cardiac surgery, and concurrent hematologic disease,
after a Heart Team discussion, a VIV TAVI was proposed.
Pre-procedural investigations included a coronary angio-
gram, showing absence of coronary artery disease, and a
computed tomography (CT) angiography to calculate the
diameter of the Mitroflow prosthesis (17 mm) and the
LMCO height from the valvular annulus (11.6 mm).
VIV implantation was performed via right femoral artery
using a CoreValve® prosthesis number 23 (Additional file 1).
A 6 Fr guide catheter, via right omeral artery, was used for
the left main coronary artery cannulation as protection
(Figs. 1 and 2).
Post-procedural angiography confirmed maintained
coronary perfusion (Fig. 3), even after the removal of the
guide wire. It also showed correct position of the pros-
thesis and its normal functioning with a transvalvular
gradient of 12 mmHg and a mild intraprosthetic regurgi-
tation (Fig. 4).
Our patient was hemodynamically stable and was
transferred to the cardiothoracic intensive care unit.
Two hours after the end of the procedure, she experi-
enced a sudden cardiac arrest with asystole and electro-
mechanical dissociation. Resuscitation maneuvers were
ineffective.
An autopsy was performed to investigate the cause of
death. The CoreValve® prosthesis was removed from the
aortic root with no signs of damage or thrombus forma-
tion (Fig. 5). The underlying Mitroflow valve appeared
free of calcium or thrombi, but its leaflets appeared
higher than the LMCO (Fig. 6). No other possible cause
for the sudden cardiac death could be found. Our hy-
pothesis was: a delayed occlusion of the LMCO by the
Fig. 1 Pre-implantation. Bioprosthesis Mitroflow number 21, Carpentier-
Edwards Physio annuloplasty ring, permanent pacemaker, temporary
pacemaker, and guide catheter into the left coronary artery
Fig. 2 CoreValve® prosthesis number 23 implanted inside the Mitroflow
prosthesis number 21
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Mitroflow leaflets, pushed upward by the late expansion
of the CoreValve® prosthesis.
Discussion
Here we described a case of VIV TAVI complicated by
coronary obstruction and sudden cardiac death. Even if
the procedure is performed with coronary protection
and perfusion is maintained at the end of the interven-
tion, our case shows that this severe adverse event may
also occur hours after the end of the TAVI, due to late
expansion of the prosthesis.
Use of bioprostheses rather than mechanical valves in
surgical aortic valve replacement has increased in recent
years [3]. Bioprostheses are characterized by progressive
leaflet degeneration, which may ultimately result in valve
stenosis, regurgitation, or both, possibly leading to
symptomatic heart failure [4, 5]. In the case of bio-
prosthesis degeneration, even if reoperation is consid-
ered the standard treatment, patients are frequently at
high risk for a second conventional surgical intervention
[6, 7]. VIV TAVI inside the previously surgically im-
planted failed aortic bioprosthesis has become a reliable
alternative to repeat surgery, because it is less invasive
and has a high rate of procedural success [1]. Moreover,
VIV procedures have lower rates of intervalvular leaks
and lower rates of atrioventricular blocks, due to the
protection given by the sewing ring of the previously im-
planted prosthesis that renders a compression of the
conduction system less probable [1].
However, the efficacy of VIV procedures has been re-
ported to be lower in specific settings [8, 9]. Worse
Fig. 3 Post-procedural coronary angiography showing normal perfusion
of left coronary arteries
Fig. 4 Mild residual aortic regurgitation
Fig. 5 CoreValve® prosthesis removed from the aortic root. Lower
left clamp is placed into the left coronary ostium
Fig. 6 Exposure of the Mitroflow prosthesis. Right clamp holds the
bioprosthesis cusp, left clamp holds the aortic root, and lower clamp
is placed into the left coronary ostium. Mitroflow leaflets appear
higher than the ostium
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outcomes are in fact reported for patients with small
surgical valves and in those with a stenotic presentation
[8]. The poor distensibility of the bioprosthetic ring ac-
counts for elevated residual transaortic mean gradients
after VIV TAVI [2]. SAPIEN valves are characterized by
annular leaflets and a relation is observed between post-
operative gradients after VIV procedure and the size of
surgical valve [1]. The same relation is not seen with
CoreValve®, due to its supra-annular leaflets that provide
a larger orifice [1].
VIV interventions may also be complicated by the
life-threatening occurrence of coronary obstruction.
The frequency of this severe event is reported to be
higher in VIV than in native valve procedures, up to
3.5% versus 0.7% of cases [2]. In a recent series by
Jabbour et al., coronary obstructions in TAVI were
found to be significantly more common after VIV
procedures [9]. Notably, in the study, delayed coron-
ary obstructions were investigated, distinguishing
them as early (occurring < 24 hours to 7 days after
the procedure) and late delayed (> 7 days). VIV was a
risk factor for both.
Coronary obstructions are usually secondary to the
displacement of the leaflet of the underlying valve to-
ward a coronary ostium, most commonly the left one
[9–12], as in the case presented.
In addition to the anatomic features known to pos-
sibly predispose to coronary obstruction in the case
of native valve procedures, namely shallow sinus of
Valsalva or low-lying coronary ostium [9, 10], in VIV
the risk is also dependent on the characteristics of
the previously implanted surgical bioprosthesis and
on the relationship of its leaflets and posts with the
coronary ostia [2].
Coronary obstructions are reported to be more com-
mon with stenotic than with regurgitant bioprostheses,
supra-annular or internally stented bioprostheses, bulky
bioprosthetic leaflets and reimplanted coronary arteries
[12]. Internally stented bioprostheses, such as Mitro-
flow, have relatively long leaflets that may extend out-
ward in a tubular fashion after a VIV implantation [12].
Stentless bioprostheses are usually implanted in a
supra-annular position, thus the valve leaflets are closer
to the coronary ostia [13].
If there is suspicion of coronary obstruction an immedi-
ate angiography must be carried out, and if diagnosis is
confirmed, percutaneous coronary intervention (PCI)
should be considered or in the case of PCI failure, emer-
gent coronary artery bypass should be considered [12]. In
a patient with high risk for coronary obstruction add-
itional preventive measures are advised, such as coronary
protection with a guidewire, leaving an undeployed stent
in the distal portion of the coronary ready to be pulled
back and implanted in the ostium if needed [10, 11]. In
selected cases, a preventive stent implantation with chim-
ney technique, even in a case of maintained perfusion of
the coronary, may be reasonable. In our center, after the
case described here, this technique was successfully per-
formed in a subsequent case of a VIV TAVI on a previous
Mitroflow number 21 prosthesis dysfunction. In addition,
the use of a retrievable valve may permit rapid prosthesis
removal in the case of coronary obstruction evidence [12].
The selection of a smaller sized valve provides less dis-
placement of bioprosthesis leaflets than the low implant-
ation does [1].
Coronary obstructions after TAVI may be acute or de-
layed, as in the case presented (early delayed, according
to Jabbour et al. [9]). No other cause for the sudden
death experienced by our patient except for LMCO ob-
struction was demonstrated by an autoptic examination.
It must, in fact, be considered that an implanted bio-
prosthesis may reach full expansion only in the first
hours after the completion of the VIV procedure; thus,
displacement of the underlying valve’s leaflets may not
be immediate [9, 13]. This mechanism is particularly
true for CoreValve® prostheses [13]. Notably, the bio-
prosthesis our patient received in 2006 was a Mitroflow
number 21. Other authors have previously underlined
the need to cautiously execute or even to avoid VIV pro-
cedures on Mitroflow bioprostheses [14].
A delayed occurrence of coronary obstruction renders
this complication, already burdened by an extremely high
mortality, even more difficult to manage. Therefore, an
adequate and careful assessment of patients who receive
indication for a VIV procedure is of paramount import-
ance. Even though rare, in fact, some complications are
sudden and fatal. Since VIV procedures have shown satis-
factory results, the best way to limit unsuccessfulness is
prevention of complications by accurate pre-selection of
patients.
Conclusions
VIV TAVI for previously implanted degenerated aortic
bioprostheses is a satisfactory alternative method to the
repeating of surgery, it is less invasive and has a high
rate of procedural success. However, coronary obstruc-
tion, a life-threatening complication, seems to occur
more frequently in VIV than in native valve TAVI.
This complication usually occurs at the time of im-
plantation, but, as reported in our case, it may also have
a delayed presentation. This highlights the importance
of adequate preoperative selection of patients as a means
of prevention.
Additional file
Additional file 1: Developing CoreValve®. (MP4 3635 kb)
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